Top Suppliers:I want be here
Related CAS#:
1532533-75-7 1532533-67-7
1532533-72-4 1532533-69-9
1532533-78-0 894783-71-2
811-92-7 45247-34-5
61-47-2 26182-60-5
1596865-36-9 1599338-47-2
1602134-60-0 1604017-34-6
1594476-56-8 1598240-76-6
1602244-45-0 1596021-56-5
1601719-64-5 1603117-23-2

1532533-75-7

1532533-75-7 structure
1532533-75-7 structure
  • Name: TGR-1202 Sulfate
  • Chemical Name: TGR-1202 Sulfate
  • CAS Number: 1532533-75-7
  • Molecular Formula: C31H26F3N5O7S
  • Molecular Weight: 669.62800
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage Casein Kinase
  • Create Date: 2016-06-30 09:46:36
  • Modify Date: 2025-09-23 21:36:35
  • Umbralisib sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach[1][2][3][4].
Name TGR-1202 Sulfate
Synonyms (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one sulfate
Description Umbralisib sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach[1][2][3][4].
Related Catalog
Target

PI3Kδ:6.2 (Kd)

CK1ϵ:180 (Kd)

PI3Kγ:1400 (Kd)

PI3Kα:>10000 (Kd)

PI3Kβ:>10000 (Kd)

In Vitro Umbralisib sulfatecauses a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM[3]. In human lymphoma and leukemia cell lines, Umbralisib sulfate (10 nM-100 μM) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner[4]. Umbralisib sulfate (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells[4].
In Vivo In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line, Umbralisib sulfate (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25[4].
References

[1]. Maharaj K, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084.

[2]. Burris HA 3rd, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496.

[3]. Swaroop Vakkalankaa, et al. Inhibition of PI3Kδ kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth.

[4]. Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99.
Melting Point 125 - 127 °C
Molecular Formula C31H26F3N5O7S
Molecular Weight 669.62800
Exact Mass 669.15100
PSA 192.04000
LogP 7.67190
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:1532533-75-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1532533-75-7 | Chemsrc address: https://www.chemsrc.com/en/baike/329090.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved